Latest News and Events
Filter by
Selections
September 1, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Read MoreJuly 29, 2021
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Read MoreJuly 14, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 6, 2021
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreJune 30, 2021